Marina C Garassino1, Luis Paz-Ares2, Rina Hui3, Corinne Faivre-Finn4, Alex Spira5, David Planchard6, Mustafa Özgüroğlu7, Davey Daniel8, David Vicente9, Shuji Murakami10, Corey Langer11, Suresh Senan12, David Spigel13, Anna Rydén14, Yiduo Zhang15, Cathy O'Brien16, Phillip A Dennis15, Scott J Antonia17. 1. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 20133, Italy. 2. Hospital Universitario 12 de Octubre, CiberOnc, Universidad Complutense & CNIO, Madrid, 28041, Spain. 3. Westmead Hospital & the University of Sydney, Sydney, NSW, 2145, Australia. 4. The University of Manchester & The Christie NHS Foundation Trust, Manchester, M20 4BX, UK. 5. Virginia Cancer Specialists Research Institute, Fairfax, VA, & US Oncology Research, The Woodlands, TX 22031, USA. 6. Institut Gustave Roussy, Department of Medical Oncology, Thoracic Group, Villejuif, 94805, France. 7. Istanbul University - Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, 34320, Turkey. 8. Sarah Cannon Research Institute/Tennessee Oncology, Chattanooga, TN 37203, USA. 9. Hospital Universitario Virgen Macarena, Seville, 41009, Spain. 10. Kanagawa Cancer Center, Yokohama, 241-8515, Japan. 11. Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA. 12. Department of Radiation Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, 1081, The Netherlands. 13. Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN 3720231, USA. 14. AstraZeneca, Gothenburg, 431 50, Sweden. 15. AstraZeneca, Gaithersburg, MD 20878, USA. 16. AstraZeneca, Cambridge, CB4 0WG, UK. 17. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Abstract
Aim: We retrospectively investigated the impact of tumor PD-L1 expression and prior chemoradiotherapy (CRT)-related variables on patient-reported outcomes (PROs) from PACIFIC. Patients & methods: PACIFIC was a Phase III study of durvalumab versus placebo after CRT in patients with unresectable, stage III non-small-cell lung cancer. If available, pre-CRT tumor tissue was tested for PD-L1 tumor-cell expression, scored at prespecified (25%) and post-hoc (1%) cut-offs. PROs were assessed using EORTC QLQ C30/-LC13. Results: Similar to the intent-to-treat (ITT) population, most PROs remained stable over time across PD-L1 and CRT subgroups, with few clinically relevant differences between treatment arms. Time to deterioration was generally similar to the ITT population. Conclusion: Neither PD-L1 expression nor prior CRT-related variables influenced PROs with durvalumab therapy. Clinical trial registration: NCT02125461 (ClinicalTrials.gov).
Aim: We retrospectively investigated the impact of tumorPD-L1 expression and prior chemoradiotherapy (CRT)-related variables on patient-reported outcomes (PROs) from PACIFIC. Patients & methods: PACIFIC was a Phase III study of durvalumab versus placebo after CRT in patients with unresectable, stage III non-small-cell lung cancer. If available, pre-CRT tumor tissue was tested for PD-L1 tumor-cell expression, scored at prespecified (25%) and post-hoc (1%) cut-offs. PROs were assessed using EORTC QLQ C30/-LC13. Results: Similar to the intent-to-treat (ITT) population, most PROs remained stable over time across PD-L1 and CRT subgroups, with few clinically relevant differences between treatment arms. Time to deterioration was generally similar to the ITT population. Conclusion: Neither PD-L1 expression nor prior CRT-related variables influenced PROs with durvalumab therapy. Clinical trial registration: NCT02125461 (ClinicalTrials.gov).
Entities:
Keywords:
durvalumab; patient-reported outcomes; programmed cell death ligand-1
Authors: David R Spigel; Corinne Faivre-Finn; Jhanelle E Gray; David Vicente; David Planchard; Luis Paz-Ares; Johan F Vansteenkiste; Marina C Garassino; Rina Hui; Xavier Quantin; Andreas Rimner; Yi-Long Wu; Mustafa Özgüroğlu; Ki H Lee; Terufumi Kato; Maike de Wit; Takayasu Kurata; Martin Reck; Byoung C Cho; Suresh Senan; Jarushka Naidoo; Helen Mann; Michael Newton; Piruntha Thiyagarajah; Scott J Antonia Journal: J Clin Oncol Date: 2022-02-02 Impact factor: 50.717